{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:23:55Z","timestamp":1782138235656,"version":"3.54.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.ophtha.2014.06.022","type":"journal-article","created":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T23:43:02Z","timestamp":1406158982000},"page":"2348-2355","source":"Crossref","is-referenced-by-count":42,"title":["Twice-Daily Brinzolamide\/Brimonidine Fixed Combination versus Brinzolamide or Brimonidine in Open-Angle Glaucoma or Ocular Hypertension"],"prefix":"10.1016","volume":"121","clinical-trial-number":[{"clinical-trial-number":"nct01309204","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01310777","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tin","family":"Aung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guna","family":"Laganovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania Josefina","family":"Hernandez Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Branch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Tsorbatzoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2014.06.022_bib1","series-title":"Terminology and Guidelines for Glaucoma","first-page":"122","year":"2008"},{"key":"10.1016\/j.ophtha.2014.06.022_bib2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/IJG.0b013e31815c5f3f","article-title":"Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project","volume":"17","author":"McCarty","year":"2008","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.ophtha.2014.06.022_bib3","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1185\/030079908X291976","article-title":"Treatment of glaucoma patients with insufficient intraocular pressure control: a survey of German ophthalmologists in private practice","volume":"24","author":"Vorwerk","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ophtha.2014.06.022_bib4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ajo.2007.06.023","article-title":"A\u00a0gap analysis approach to assess patient persistence with glaucoma medication","volume":"144","author":"Lee","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.06.022_bib5","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1185\/03007990903260129","article-title":"Glaucoma medication persistence with a fixed combination versus multiple bottles","volume":"25","author":"Higginbotham","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ophtha.2014.06.022_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archophthalmol.2009.384","article-title":"Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study","volume":"128","author":"Higginbotham","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.06.022_bib7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/jamaophthalmol.2013.188","article-title":"Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%","volume":"131","author":"Katz","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.06.022_bib8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1089\/jop.2012.0235","article-title":"Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%\/brimonidine 0.2%","volume":"29","author":"Nguyen","year":"2013","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2014.06.022_bib9","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2147\/OPTH.S46881","article-title":"Six-month results from a phase III randomized trial of fixed-combination brinzolamide 1%\u00a0+ brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension","volume":"7","author":"Whitson","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.06.022_bib10","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/eye.2013.83","article-title":"Fixed-combination brinzolamide 1%\/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies","volume":"27","author":"Realini","year":"2013","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2014.06.022_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1442-9071.2012.02823.x","article-title":"Patient satisfaction with topical ocular hypotensives","volume":"41","author":"Kerr","year":"2013","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.06.022_bib12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ophtha.2005.10.034","article-title":"Patient-reported behavior and problems in using glaucoma medications","volume":"113","author":"Sleath","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.06.022_bib13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/IJG.0b013e3181815421","article-title":"Determinants of adherence to glaucoma medical therapy in a long-term patient population","volume":"18","author":"Djafari","year":"2009","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.ophtha.2014.06.022_bib14","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","article-title":"Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review","volume":"112","author":"Olthoff","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2014.06.022_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jps.2600630304","article-title":"Drop size and initial dosing frequency problems of topically applied ophthalmic drugs","volume":"63","author":"Chrai","year":"1974","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.ophtha.2014.06.022_bib16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjo.86.4.418","article-title":"Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication","volume":"86","author":"Pisella","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.06.022_bib17","first-page":"1","article-title":"Considerations in glaucoma therapy: fixed combinations versus their component medications","volume":"4","author":"Higginbotham","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2014.06.022_bib18","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","article-title":"Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials","volume":"112","author":"van der Valk","year":"2005","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014005363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642014005363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T07:45:53Z","timestamp":1621064753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642014005363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0161642014005363"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2014.06.022","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}